---
title: "Moleculin Biotech Gains European Approval for Phase 3 Trial"
date: "2025-02-11 22:48:43"
summary: "Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart PortfolioThe latest update is out from..."
categories:
  - "tipranks_announcements"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks_announcements"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1911898180-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

The latest update is out from Moleculin Biotech ( [(MBRX)](https://www.tipranks.com/stocks/mbrx) ).

On February 11, 2025, Moleculin Biotech announced receiving regulatory approval in Europe to start recruiting for its Phase 3 MIRACLE trial, evaluating Annamycin combined with Cytarabine for treating relapsed or refractory acute myeloid leukemia. The trial will include sites in the US, Europe, and the Middle East. The announcement signifies a crucial step in advancing their pivotal clinical trial, aiming for unblinded preliminary data from the first 45 subjects in the second half of 2025, potentially enhancing their market position in cancer therapeutics.

**More about Moleculin Biotech**

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Their lead program, Annamycin, aims to overcome multidrug resistance and reduce cardiotoxicity related to anthracyclines, targeting relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases. The company is also working on other treatments targeting cancer and pathogenic viruses.

**YTD Price Performance:** -60.23%

**Average Trading Volume:** 95,370

**Technical Sentiment Consensus Rating:** Buy

**Current Market Cap:** $2.7M

See more data about MBRX stock on [TipRanks’ Stock Analysis page](https://www.tipranks.com/stocks/mbrx/stock-analysis).

Trending Articles:
------------------

* [Elon Musk’s Brother and Tesla Director Kimbal Sells $28M Worth of Stock](https://www.tipranks.com/news/elon-musks-brother-and-tesla-director-kimbal-sells-28m-worth-of-stock)
* [APLT Lawsuit Alert! Class Action Against Applied Therapeutics, Inc.](https://www.tipranks.com/news/aplt-lawsuit-alert-class-action-against-applied-therapeutics-inc)
* [‘Bullish Confirmation Coming,’ Says Investor About Super Micro Computer Stock](https://www.tipranks.com/news/bullish-confirmation-coming-says-investor-about-super-micro-computer-stock)

[tipranks_announcements](https://www.tipranks.com/news/company-announcements/moleculin-biotech-gains-european-approval-for-phase-3-trial)
